Literature DB >> 22979918

Response to 'Fragment of tegument protein pp65 of human cytomegalovirus induces autoantibodies in BALB/c mice'.

Gn Kim, Think-You Kim.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22979918      PMCID: PMC3580504          DOI: 10.1186/ar4023

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


× No keyword cloud information.

We read with interest the recent paper by Hsieh and colleagues [1] asserting that cytomegalovirus (CMV) induces systemic lupus erythematosus (SLE) in genetically susceptible individuals. This assertion is based on the idea that SLE-associated autoantibodies that had been induced by a certain fragment of CMV were found in rodents. However, our previous studies have reported that autoantibodies detected in SLE and viral infection are different, especially with regard to the anti-microtubule organizing center with microtubule (anti-MTOC-MT) [2-4]. We conducted a retrospective study comparing autoantibodies in three groups: anti-CMV IgM-positive SLE patients (SLE-CMV group); anti-CMV IgM-positive patients without SLE (CMV group); and anti-CMV IgM-negative SLE patients (SLE group). This study was approved by the institutional review board of Hanyang University Medical Center. Autoantibodies from 245 patients were analyzed from January 2005 to March 2012 by the autoimmune target (AIT) test, which was developed to overcome the limitations of the antinuclear antibody test using the human macrophage cell line (IT-1) as a substrate [2]. What is noteworthy is that anti-MOTC-MT was highly detected in the CMV group, while it was not detected in all SLE patients regardless of CMV infection. Moreover, if CMV is a cause of SLE, detected autoantibodies between the SLE-CMV and CMV groups should overlap, but they show a clear distinction (Table 1).
Table 1

Immunofluorescence patterns and titers of AIT test in SLE-CMV, SLE and CMV groups

Titer

Patterns from AIT test≤1:201:401:801:1601:3201:6401:1280≥1:2560Total
SLE-CMV groupa
 Homogeneous2911
 Homogeneous + speckled41317
 Homogeneous + cytoplasmic11
 Homogeneous + diffuse granular44
 Homogeneous + speckled + cytoplasmic33
 Speckled189
 Speckled + cytoplasmic112
 Diffuse granular + cytoplasmic11
 Diffuse cytoplasmic + speckled33
 Diffuse cytoplasmic + diffuse granular22
 Total00010614553
SLE groupb
 Homogeneous121518
 Homogeneous + speckled233338
 Homogeneous + cytoplasmic22
 Homogeneous + diffuse granular11213
 Homogeneous + speckled + cytoplasmic2147
 Speckled5353447
 Speckled + cytoplasmic133310
 Diffuse granular + cytoplasmic2158
 Diffuse granular15713
 Diffuse cytoplasmic + speckled99
 Diffuse cytoplasmic + diffuse granular112
 Diffuse cytoplasmic + nucleolar123
 Total0000121022126170
CMV groupc
 MTOC-MT4411111
 MTOC-MT + IF + speckled11215
 Speckled22
 Negative44
 Total4176112022

aSLE-CMV group, anti-CMV IgM-positive SLE patients; bSLE group, anti-CMV IgM-negative SLE patients; cCMV group, anti-CMV IgM-positive patients without SLE. The AIT test was performed using an indirect immunofluorescent test kit (IT-AIT™; ImmunoThink Co., Seoul, Republic of Korea). In the CMV group, anti-MTOC-MT-positive patients accounted for 72.7% of the total patients in the CMV group and 88.9% of autoantibody-positive patients, but in the SLE-CMV group, anti-MTOC-MT was not detected at all (P < 0.001). Patients in the SLE-CMV group showed high titers of over 1:640 except for one who received steroid pulse therapy just before the test, but the proportion of patients in the CMV group with a titer over 1:640 was not more than 13.6% (P < 0.001). In addition, most of the autoantibody frequently found in the SLE-CMV group was not found in the CMV group. AIT, autoimmune target; CMV, cytomegalovirus; IF, intermediate filament; MTOC-MT, microtubule organizing center with microtubule; SLE, systemic lupus erythematosus.

Immunofluorescence patterns and titers of AIT test in SLE-CMV, SLE and CMV groups aSLE-CMV group, anti-CMV IgM-positive SLE patients; bSLE group, anti-CMV IgM-negative SLE patients; cCMV group, anti-CMV IgM-positive patients without SLE. The AIT test was performed using an indirect immunofluorescent test kit (IT-AIT™; ImmunoThink Co., Seoul, Republic of Korea). In the CMV group, anti-MTOC-MT-positive patients accounted for 72.7% of the total patients in the CMV group and 88.9% of autoantibody-positive patients, but in the SLE-CMV group, anti-MTOC-MT was not detected at all (P < 0.001). Patients in the SLE-CMV group showed high titers of over 1:640 except for one who received steroid pulse therapy just before the test, but the proportion of patients in the CMV group with a titer over 1:640 was not more than 13.6% (P < 0.001). In addition, most of the autoantibody frequently found in the SLE-CMV group was not found in the CMV group. AIT, autoimmune target; CMV, cytomegalovirus; IF, intermediate filament; MTOC-MT, microtubule organizing center with microtubule; SLE, systemic lupus erythematosus. CMV becomes latent in multiple organs and can later be reactivated during severe dysregulation of the immune system. In our study, over 90% of patients in the three groups were anti-CMV IgG-positive. Detection of anti-CMV IgG implies the presence of latent virus, but anti-CMV IgG does not protect the individual from reactivation of the latent virus. In contrast, anti-CMV IgM responses are often seen during reactivation of CMV, so it seems that CMV infection in the SLE-CMV group was not caused by primary infection but by reactivation of CMV. MTOC, cytokines and T cells are closely coordinated to maintain the immune system [5] and anti-MTOC-MT is not found in SLE patients owing to impairment of the immune system. In conclusion, we postulate that CMV is not sufficiently intense to cause SLE, but is reactivated in some SLE patients as an innocent bystander.

Abbreviations

AIT: autoimmune target; CMV: cytomegalovirus; MTOC-MT: microtubule organizing center with microtubule; SLE: systemic lupus erythematosus.

Competing interests

Think-You Kim holds patents relating to the IT-1 cell line.
  5 in total

1.  MTOC-MT is a major target antigen of autoantibody detected by autoimmune target tests in patients with hepatitis A virus infection.

Authors:  Jung-U K Sir; Think-You Kim
Journal:  J Clin Pathol       Date:  2010-10-05       Impact factor: 3.411

2.  Autoantibodies are commonly detected by the AIT test in patients with chronic hepatitis C virus infection.

Authors:  Jung-U K Sir; Think-You Kim
Journal:  J Viral Hepat       Date:  2009-09-25       Impact factor: 3.728

3.  Limitations of antinuclear antibody tests (HEp-2) are overcome with the autoimmune target test (IT-1) in systemic lupus erythematosus.

Authors:  La-He Jearn; Duck-An Kim; Think-You Kim
Journal:  J Rheumatol       Date:  2009-08       Impact factor: 4.666

4.  Fragment of tegument protein pp65 of human cytomegalovirus induces autoantibodies in BALB/c mice.

Authors:  Ao-Ho Hsieh; Yí-Jyun Jhou; Chung-Ting Liang; Mingi Chang; Shih-Lien Wang
Journal:  Arthritis Res Ther       Date:  2011-10-11       Impact factor: 5.156

5.  MTOC translocation modulates IS formation and controls sustained T cell signaling.

Authors:  Noa B Martín-Cófreces; Javier Robles-Valero; J Román Cabrero; María Mittelbrunn; Mónica Gordón-Alonso; Ching-Hwa Sung; Balbino Alarcón; Jesús Vázquez; Francisco Sánchez-Madrid
Journal:  J Cell Biol       Date:  2008-09-08       Impact factor: 10.539

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.